Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877551 · ClinicalTrials.gov registry record · NA
Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT01877551 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 27 participants.
The verdict
NCT01877551, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
Rates of cardiovascular disease and diabetes are more than 2-fold greater in HIV infected people than the general population. Protease inhibitor booster antiretroviral therapy (PI-ART) which is used by \~50% of HIV infected people in the USA is an established risk factor for diabetes. Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile salt, improves insulin sensitivity in HIV uninfected subjects, although the mechanisms for these benefits are unclear. This study will explore the hypothesis that TUDCA will improve insulin action in people with HIV who are receiving PI-ART. Further, this project will clarify the molecular mechanisms responsible for these improvements potentially benefiting society, irrespective of HIV status.
Interventions
- OTHER Placebo tablet
- DRUG Tauroursodeoxycholic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-09 |
| Est. Completion | 2018-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01877551
The ClinicalTrials.gov registry entry for NCT01877551 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo tablet is the first listed.
NCT01877551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01877551 about?
NCT01877551 is a clinical study titled "Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance". Rates of cardiovascular disease and diabetes are more than 2-fold greater in HIV infected people than the general population. Protease inhibitor booster antiretroviral therapy (PI-ART) which is used by \~50% of HIV infected people in the USA is an established risk factor for diabetes. Tauroursodeoxy...
What is the current status of trial NCT01877551?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2013-09. Estimated completion is 2018-05.
What interventions are being tested in trial NCT01877551?
The interventions under investigation include: Placebo tablet (OTHER), Tauroursodeoxycholic acid (DRUG).
Who is sponsoring clinical trial NCT01877551?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.